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Abstract
Background: We compared all-cause mortality, major macrovascular events (MACE) and diabetes-related hospitalizations
in T2DM-incident patients newly treated with metformin (MET) versus sulphonylureas (SU) monotherapy and
in T2DM-prevalent patients newly treated with MET+SU versus MET+DPP4-inhibitor combination therapy.
Methods: We analysed anonymized data obtained from a German health fund. Patients were included when
they had started MET versus SU therapy or MET+SU versus MET+DPP4 therapy between 01/07/2010 and 31/
12/2011. Observation started with the first MET/SU prescription or the first prescription of the second agent
of a MET+SU/MET+DPP4 combination therapy. Follow-up time lasted until the end of data availability (a minimum of
12 months), death or therapy discontinuation.
Results: In total, 434,291 T2DM-prevalent and 35,661 T2DM-incident patients were identified. Of the identified
T2DM-incident patients, 904/7,874 started SU/MET monotherapy, respectively, with a mean age of 70.1/61.4 years
(54.6/50.3 % female; Charlson Comorbidity Index (CCI) 1.4/2.2; 933/7,350 observed SU/MET patient years). 4,157/1,793
SU+MET/DPP4+MET therapy starters had a mean age of 68.1/62.2 years (53.4/50.8 % female; CCI 2.8/2.6; 4,556/1,752
observed SU+MET/ DPP4+MET patient years).
In a propensity score matched (PSM) comparison, the HRs (95 % CIs) associated with SU monotherapy compared to
MET monotherapy exposure were 1.4 (0.9–2.3) for mortality, 1.4 (0.9–2.2) for MACE, 4.1 (1.5–10.9) for T2DM
hospitalizations and 1.6 (1.2–2.3) for composite event risk. In a multivariable Cox regression model, SU monotherapy
was associated with higher mortality (aHR 2.0; 1.5–2.6), higher MACE (aHR 1.3; 1.0–1.7) and higher T2DM
hospitalizations (aHR 2.8; 1.8–4.4), which corresponded with a higher composite event risk (aHR 1.8; 1.5–2.1).
No significant differences in event rates were observed in the PSM comparison between DPP4+MET/SU+MET
combination therapy starters and in the multivariable Cox regression analysis.
Conclusions: Our results show that SU monotherapy may be associated with increased mortality, MACE and
T2DM hospitalizations, compared to MET monotherapy. When considering SU therapy, the associated cardiovascular
risk should also be taken into account.
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Background
Amongst the most common chronic diseases, type 2
diabetes mellitus (T2DM) presents some of the greatest
clinical and health economic challenges [1]. In addition to
burdens directly associated with the underlying disease,
T2DM patients have an increased frequency of micro-
and macrovascular complications and hospitalizations as
well as increased mortality rates [2–7].
The primary goal of diabetes treatment is to control
blood glucose levels [8, 9]. If treatment with metformin
(MET) is insufficient, treatment guidelines recommend
second-line treatment with agents including sulphony-
lureas (SU), thiazolidinediones, alpha-glucosidase inhibi-
tors, dipeptidyl peptidase-4 inhibitors (DPP4), basal
insulin, SGLT-2 inhibitors and glucagon-like peptide-1
(GLP-1) receptor agonists [8, 9].
Previous observational studies have shown that a sub-
stantial number of T2DM patients receive SUs [10, 11].
In fact, in countries like Germany, public agencies fre-
quently see SUs as a main comparator therapy when
assessing the potential value and reimbursement price of
new second-line T2DM treatment agents such as DPP4s
or GLP1s [12–14]. That being said, findings from
clinical trials and observational studies have also
raised concerns about the effectiveness and safety of
SU treatment, especially in terms of its association
with risks of hypoglycaemic as well as macrovascular
events [11, 15–19]. Specifically, a recent UK analysis
concluded that both SU monotherapy (compared to
MET monotherapy) and SU combination therapy with
MET (compared to MET+DPP4 combination therapy)
are associated with an increased macrovascular/mor-
tality event risk [11, 19].
In this study, we assessed all-cause mortality, major
macrovascular events (MACE) and diabetes-related
hospitalizations in T2DM-incident patients newly treated
with MET versus SU monotherapy and in T2DM-




We used an anonymized dataset obtained from the
German health fund AOK PLUS (2010–2012) which
initially included all T2DM-prevalent patients [at least
one outpatient or inpatient T2DM diagnosis (ICD-10
codes: E11.-) in 01/07/2010-31/12/2011] who were in-
sured by this health fund for the entire study period.
The dataset contained information on patient socio-
demographics, outpatient prescriptions, diagnosis-
associated outpatient visits to GPs and specialists, and
finally inpatient treatment in hospitals.
All patients were followed from the moment they were
enrolled in the study until the occurrence of the
outcomes of interest or until the end of the study
period (whichever came first). By applying additional
inclusion criteria, T2DM-incident patients were iden-
tified as a subgroup of all T2DM-prevalent patients.
These patients had at least one outpatient/inpatient
T2DM diagnosis recorded in 01/07/2010–31/12/2011
without any previous T2DM diagnosis and without any
prescriptions of an antidiabetic agent (ATC groups: A10*)
in the preceding 6 months.
SU monotherapy versus MET monotherapy
The study included T2DM-incident patients who started
either MET or SU monotherapy between 01/07/2010
and 31/12/2011 without having received any prior anti-
diabetic medication during the preceding 180 days
(Figs. 1 and 2). Observation started with the date of the
first observed MET/SU prescription; follow-up time for
each patient was at least 12 months (with death as an
exception) and lasted until the first observed event,
death, therapy discontinuation (treatment gap >180 days
or prescription of another agent) or the end of 2012,
whichever came first. All patients were followed with re-
gard to the following events:
 MACE
○ Hospitalizations with stroke (ICD-10 codes:
I60.-/I61.-/I62.-/I63.-/I64.-)
○ Hospitalizations with acute myocardial infarction
(ICD-10 codes: 10 I21.-)
○ Hospitalizations with congestive heart failure
(CHF) (ICD-10 codes: 10 I50.-)
○ Hospitalizations with coronary revascularizations
(OPS 5-361/5-362/5-363)
○ Hospitalizations with percutaneous transluminal
vascular interventions and stent implantations
(OPS 8-836/8-837/8-84)
○ Hospitalizations with peripheral vascular disease
(ICD-10 code: 10 I73.9)
○ Hospitalizations with angina pectoris (ICD-10
codes: 10 I20.-)
 T2DM-related hospitalizations
○ Hospitalizations with T2DM/acute hypoglycaemia
as main diagnosis (ICD-10 codes: E11.-/ E16.0/
E16.1/E16.2)
 Death (any cause)
 Composite outcome consisting of MACE, T2DM-
related hospitalizations, and all-cause death.
In order to reliably differentiate between acute events
and treatment for previous diagnoses/events, this ana-
lysis only considered ICD-10 diagnoses or documented
procedures (i.e. documented by means of German OPS
codes) to represent an event if they were the main mo-
tivation for acute hospitalization. The main outcome
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used in this study was a composite outcome (occurrence
of any of the above events); in secondary analyses, the
three event types were analysed separately.
SU+MET combination therapy versus DPP4+MET
combination therapy
Our analyses of SU+MET combination therapy versus
DPP4+MET combination therapy exclusively included
T2DM-prevalent patients who had been prescribed
MET monotherapy before and who started either MET-
SU or MET-DPP4 combination therapy (combination
therapy starters; first prescriptions needed to overlap
within 30 days) between 01/07/2010 and 31/12/2011
without having received any prior SU/DPP4 medication
(for the preceding 180 days). Data are presented in
Figs. 1 and 3. Follow-up started with the first ob-
served prescription of the second dual combination
agent. All patients were followed with respect to the
events as defined above. The follow-up period ended
at therapy discontinuation (treatment gap >180 days or
prescription of another agent), at death/first observed
event or at the end of data availability (31/12/2012).
Statistical analysis
Differences in event risk for patients who received
MET/SU monotherapy or SU+MET/DPP4+MET com-
bination therapy were reported as unadjusted hazard
ratios (HRs) in a Cox regression model censoring for
death in the analyses addressing time to first MACE
and time to first T2DM-related hospitalization and,
additionally, censoring for therapy discontinuation/
end of follow-up period for all outcome categories in-
cluding death. Furthermore, the percentage of event-
free patients over time was depicted by means of
Kaplan Meier (KM) curves, and log-rank tests were
used for testing statistical significance of differences.
To address the issue of confounding, two additional
analyses were conducted: an analysis of event rates in pro-
pensity score matched patient samples and a multivariate
Cox regression analysis using time to event as the
dependent variable and reporting adjusted HRs (aHRs).
In the propensity score matching (PSM) procedure,
SU-exposed patients (either mono or in combination
with MET) were matched to SU non-exposed patients
(MET mono or DPP4+MET) by propensity score. Only
patients with complete (non-imputed) data were
Fig. 1 Patient inclusion/exclusion criteria and observational periods for analysed T2DM cohorts
Wilke et al. Journal of Diabetes & Metabolic Disorders  (2016) 15:28 Page 3 of 10
included in the analyses. Propensity scores were calculated
using logistic regression estimation (with group affiliation as
the dependent variable) including age, gender, age-adjusted
Charlson Comorbidity Index (CCI; Additional file 1:
Table S2) and adapted Diabetes Complications Severity
Index (aDCSI; Additional file 2: Table S1) [4] as general
independent variables, even if a certain overlap existed be-
tween some of these variables. Furthermore, the following
variables related to the six months prior to the index pre-
scription were included as independent variables in case
these variables significantly influenced group exposition:
the number of general practitioner visits, any previous
Fig. 2 Patient sample of T2DM-incident patients who started SU/MET monotherapy
Fig. 3 Patient sample of T2DM-prevalent patients who started MET+SU/MET+DPP4 combination therapy
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observed micro-/macrovascular complications and pre-
scription of antithrombotic, antihypertensive or lipid low-
ering medication. A backward elimination approach was
used to eliminate any variables that did not reach signifi-
cance in explaining group exposition; in such cases, these
variables were excluded from the PSM model. In any case,
models included age, gender and age-adjusted CCI. For
the PSM matched cohorts, separate estimates of HRs were
calculated following the methodology as described above.
In order to analyse independent factors associated with
the observed event risk, additional multivariable Cox re-
gression analyses were conducted covering MET/SU
monotherapy patients (Model 1) and SU+MET/DPP4
+MET combination therapy patients (Model 2); results
were reported as aHRs. In addition to the exposure to either
MET/SU monotherapy or SU+MET/DPP4+MET combin-
ation therapy, age (as dichotomous variable with a cut-off
point at 65 years), gender, age-adjusted CCI and aDCSI
were included in these models as independent variables.
All reported p-values were two-sided, and 95 % CIs
were calculated for HRs/aHRs. All descriptive analyses
were performed with Microsoft SQL Server 2008 and
Microsoft Excel 2010. All other statistical analyses were
performed with SPSS 17.0.
Results
T2DM patient characteristics
In our study population, a total of 434,291 T2DM-
prevalent and a subgroup of 35,661 T2DM-incident pa-
tients were identified (Table 1, Figs. 2 and 3). Of the
T2DM-prevalent patients, 56.2 % were female and their
mean age was 70.2 years. We also observed a high
number of comorbidities per patient in this sample,
expressed as a mean CCI (without age factor) of 3.7,
which indicates a significant burden in terms of comor-
bidities experienced per patient.
SU monotherapy versus MET monotherapy
Of the T2DM-incident patients in our study, 904 patients
who were new initiators of SU monotherapy were signifi-
cantly older (mean age of 70.1 years), were more likely to
be female (54.6 %) and had a significantly higher mean
age-adjusted CCI (2.23) than the 7,874 therapy-naïve users
of MET monotherapy [mean age of 61.4 years (p <0.001),
50.3 % female (p <0.050), mean age-adjusted CCI of 1.44
(p <0.001); Table 1]. We observed 933 patient years of SU
monotherapy exposure (mean follow-up period 376.9 days)
and 7,850 patient years of MET monotherapy exposure
(mean follow-up period 363.9 days).
In the unmatched patient sample comparisons (Table 2;
supplemental KM curves in Additional file 3: Figure S3),
the HRs (95 % CIs) associated with SU exposure in com-
parison to MET exposure were 3.3 (2.6–4.3) for mortality,
1.9 (1.4–2.4) for MACE, 3.0 (1.9–4.6) for T2DM-related
hospitalizations and 2.5 (2.1–3.0) for composite event risk.
In the PSM comparison which included 1,460 patients
(730 patients per group, overlap of propensity scores in
Cohort 1, incorporating patients who received MET/SU
monotherapy are described in Additional file 4: Figure S1),
the HRs (95 % CIs) associated with SU exposure in com-
parison to MET exposure were 1.4 (0.9–2.3) for mortality,
1.4 (0.9–2.2) for MACE, 4.1 (1.5–10.9) for T2DM-related
hospitalizations and 1.6 (1.2–2.3) for composite event rates
(Table 2; KM curves in Additional file 3: Fig. S3).




T2DM-incident patients who initiated




T2DM-prevalent patients who initiated either
MET+SU or MET+DPP4 combination therapy
Unmatched PS-matched Unmatched PS-matched








N 35,661 904 7,874 730 730 434,291 4,157 1,793 1,253 1,253
Age in years 65.91 70.15 61.43 (p <0.001) 67.66 67.47 70.24 68.09 62.2 (p <0.001) 64.61 64.8
Gender (female) 54.17 % 54.65 % 50.34 % (p <0.050) 53.29 % 52.47 % 56.23 % 53.36 % 50.81 % (p <0.100) 52.35 % 51.80 %
CCI without age
factor (baseline)




1.92 % 5.20 % 4.19 % (p >0.100) 4.79 % 4.38 % 5.18 % 2.09 % 3.18 % (p <0.050) 1.52 % 1.92 %
Antithrombotic
agent (baseline)
15.70 % 21.68 % 15.76 % (p <0.001) 16.58 % 15.07 % 27.74 % 20.88 % 18.24 % (p <0.050) 17.32 % 18.60 %
Antihypertensive
(baseline)
4.75 % 5.09 % 5.28 % (p >0.100) 4.79 % 4.11 % 9.19 % 8.80 % 7.36 % (p <0.100) 8.06 % 7.58 %
Lipid lowering
drugs (baseline)
18.20 % 22.68 % 22.87 % (p >0.100) 22.19 % 22.47 % 32.94 % 32.02 % 33.80 % (p >0.100) 28.49 % 32.00 %
Legend: The table lists the sociodemographic characteristics of the observed samples. These data refer to the start of data availability (01/01/2010) for age/gender
and to the 6-month baseline period before the start of observation (for the cohort of T2DM-prevalent patients, this is 01/01/2012)
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In the multivariable Cox regression models (Table 2;
Additional file 5: Figure S5), older age, higher age-adjusted
CCI and higher aDCSI were associated with increased
MACE/death rates. With respect to hospitalization rates,
female gender was associated with lower event rates, while
a higher aDCSI was associated with higher event rates. SU
monotherapy was associated with higher mortality rates
(aHR 2.0; 1.5–2.6), higher MACE rates (aHR 1.3; 1.0–1.7)
and higher T2DM-related hospitalization rates (aHR 2.8;
95 % CI: 1.8–4.4). This corresponded with higher compos-
ite event rates (aHR 1.8; 1.5–2.1).
SU+MET combination therapy versus DPP4+MET
combination therapy
Among the T2DM-prevalent patients, 4,157 patients who
were newly prescribed with a SU+MET combination ther-
apy were significantly older (mean age of 68.1 years), were
more likely to be female (53.4 %) and had a significantly
higher mean age-adjusted CCI (2.79) than the 1,793 pa-
tients with newly prescribed DPP4+MET combination
therapy [mean age of 62.2 years (p <0.001); 50.8 %
female (p <0.050) and a mean age-adjusted CCI of
2.56 (p <0.001); Table 1]. We observed 4,556 patient
years of SU+MET exposure (mean follow-up period
of 400.0 days) and 1,752 patient years of DPP4+MET
exposure (mean follow-up period of 356.6 days).
In the unmatched patient sample comparisons (Table 3;
Additional file 6: Figure S4), estimated HRs (95 % CIs)
associated with SU+MET exposure in comparison to
MET+DPP4 exposure were 1.5 (1.0–2.4) for mortality,
1.0 (0.8–1.4) for MACE, 0.9 (0.6–1.5) for T2DM hospi-
talizations, and 1.1 (0.9–1.3) for composite event rates.
In the PSM comparison which included 2,506 patients
(1,253 patients per group, overlap of propensity scores in
Cohort 2, incorporating patients who received SU+MET
and DPP4-MET combination therapy are described in
Additional file 7: Figure S2), HRs (95 % CIs) associated
with SU+MET exposure were 1.3 (0.7–2.6) for mortality,
0.7 (0.5–1.1) for MACE, 0.9 (0.4–1.7) for T2DM hospitali-
zations and 0.8 (0.6–1.2) for composite event rates
(Table 3; Additional file 8: Figure S8). In the multivariable
Cox regression models (Table 3; Additional file 9: Figure S6),
older age, higher age-adjusted CCI, higher aDSCI and
male gender were associated with an increased risk of
all-cause events (including MACE, deaths and T2DM-
related hospitalizations). When we compared SU+MET
combination therapy to DPP4+MET combination therapy,
as was done in the PSM analysis, no statistically significant
results were found (Table 3; Additional file 10: Figure S7).
Discussion
The results of this study indicate that SU monotherapy
may be associated with an increased risk of death, MACE
and hospitalizations for T2DM patients compared to
MET monotherapy, taking into account the differences in
patient characteristics. This was seen in crude as well as
multivariate Cox regression analyses, but due to small
sample sizes this could not be confirmed for all observed
outcomes in the PSM comparison. However, point esti-
mates indicated similar associations, and we also observed
Table 2 Crude Hazard Ratios, Hazard Ratios in PSM-matched cohorts and adjusted Hazard Ratios for death, first MACE, first T2DM-re-
lated hospitalization and composite outcome in patients treated with SU monotherapy (n = 904) versus MET monotherapy (n
= 7,874); PSM: n = 1,253 per group
Events Crude HR (95 %-CI) p PSM HR (95 %-CI) p aHR (95 %-CI) p
Death 3.3 (2.567–4.344) <0.001 1.4 (0.907–2.332) 0.120 2.0 (1.538–2.635) <0.001
MACE 1.9 (1.436–2.399) <0.001 1.4 (0.899–2.185) 0.137 1.3 (1.033–1.743) <0.050
T2DM-related hospitalization 3.0 (1.927–4.556) <0.001 4.1 (1.551–10.930) <0.005 2.8 (1.807–4.407) <0.001
Composite outcome (any event, whatever came first) 2.5 (2.098–2.995) <0.001 1.6 (1.183–2.259) <0.005 1.8 (1.480–2.132) <0.001
HRs/aHRs reported for SU exposure in comparison to MET exposure
HR hazard ratio, aHR adjusted hazard ratio, MET metformin, SU sulphonylureas, DPP4 dipeptidyl peptidase-4 inhibitor, PSM propensity score matching, CI confi-
dence interval 95 %
Table 3 Crude Hazard Ratios, Hazard Ratios in PSM-matched cohorts and adjusted Hazard Ratios for death, first MACE, first
T2DM-related hospitalization and composite outcome in patients treated with SU +MET (n = 4,157) versus DPP-4 +MET (n = 1,793); PSM:
n = 1,253 per group
Events Crude HR (95 %-CI) p PSM HR (95 %-CI) p aHR (95 %-CI) p
Death 1.5 (0.966–2.414) 0.070 1.3 (0.662–2.596) 0.437 1.3 (0.792–2.005) 0.330
MACE 1.0 (0.804–1.362) 0.736 0.7 (0.487–1.123) 0.157 0.8 (0.650–1.110) 0.850
T2DM-related hospitalization 0.9 (0.588–1.446) 0.725 0.9 (0.446–1.679) 0.668 0.8 (0.527–1.320) 0.438
Composite outcome (any event, whatever came first) 1.1 (0.883–1.344) 0.425 0.8 (0.616–1.167) 0.313 0.9 (0.734–1.126) 0.382
HRs/aHRs reported for SU+MET exposure in comparison to DPP4+MET exposure
HR hazard ratio, aHR adjusted hazard ratio, MET metformin, SU sulphonylureas, DPP4 dipeptidyl peptidase-4 inhibitor, PSM propensity score matching, CI confi-
dence interval 95 %
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a trend of non-significant increased risk for MACE
and death in the SU group in the PSM comparison.
Furthermore, there was a significantly higher risk of
T2DM-related hospitalizations in the SU group in the
PSM analysis which also translated, together with the
aforementioned results, into a lower percentage of
PS-matched patients treated with MET experiencing
an all-cause event.
The higher SU-associated T2DM hospitalization risk
may underpin the disadvantage of higher rates of
hypoglycaemia associated with SU therapy [20], some-
thing which has also been confirmed by earlier studies
and reported in a recently published review [21–23]. In
addition, another systematic review and meta-analysis as
well as another study found that patients receiving SU
treatment had an increased all-cause mortality risk
[16, 24]; this, however, could not be confirmed in every
study [25]. Furthermore, a UK-based study which was very
similar to the one reported here compared MACE/mortal-
ity risk among T2DM-incident patients treated with either
SU or MET monotherapy; this study did not include
T2DM-related hospitalizations as an event type. It
concluded that SU monotherapy was associated with in-
creased MACE/mortality risk [11]. Another study which
examined SU monotherapy in T2DM patients in compari-
son to MET monotherapy reported that SU users experi-
enced treatment failure (defined as progression to a
combination of oral anti-hyperglycaemia drug therapy, in-
sulin use or an HbA1C >7.5 %) significantly earlier and
more frequently than MET monotherapy users [26].
While further examinations of potential risk factors re-
lated to an increased mortality/MACE/hospitalization risk
associated with SU monotherapy are not available in this
current study, evidence from previous studies indicates
that several factors may contribute to the underlying risks,
including weight gain [27–30], links to cancer [31, 32],
increased insulin resistance and the underliying SU mech-
anism of action [33–36].
A German analysis covering data provided by 1,201 GPs
reported a lower macrovascular event frequency under
DPP4 treatment in comparison to SU treatment. This
could not be confirmed in our study. However, in this
study, events were identified through GP diagnoses only;
these may have described more existing co-morbidities in
T2DM patients than incident events in our definition,
which identified events through acute hospitalizations
only. Moreover, we observed patients who received either
SU or MET monotherapy or SU+MET or DPP4+MET
combination therapy only, whereas this analysis only ex-
cluded concomitant insulin therapy but allowed for all
other antidiabetic agents [24]. Furthermore, our analysis
covered prescriptions and outpatient treatment by a larger
number of physicians (12,419 outpatient physicians, with
5,055 different GPs and outpatient specialists involved).
In contrast to our study, a similar analysis based on
a retrospective sample of UK patients found all-cause
mortality to be lower in the DPP4+MET group; a
similar trend was also observed for MACE risk [24].
This UK analysis was based on a significantly larger
sample size of 33,983 MET+SU and 7,864 MET
+DPP4 patients in the unmatched comparison and
13,802 patients in the PSM comparison. In addition,
median follow-up time was also longer in the UK
study when compared to our study. Furthermore, the
patient characteristics in our study also differed sig-
nificantly from the UK analysis: whereas mean age in
our PSM cohorts was 64.6–64.8 years, mean age in
the UK-PSM cohorts was 59.8–60.4 years. Results
similar to the abovementioned UK analysis were
found in another large study [24]; our results were
confirmed in several other retrospective database
studies [24, 37].
There may be specific clinical reasons why SU/MET
+SU patients received this specific type of therapy
(e.g. low risk of hypoglycaemia). In choosing SU ther-
apy, MET contraindications may have played a major
role. We observed MET contraindications in 44 % of
the patients contained in our database. This may also
explain event/mortality rate differences in the un-
matched comparisons between MET/SU and MET
+SU/MET+DPP4 groups. Other reasons for choosing
a specific antidiabetic therapy were unknown to us,
but could have confounded the results. Furthermore,
we observed comparatively old/comorbid T2DM pa-
tients. This is due to the characteristics of those in-
sured in the health care fund which provided the
data. This means that T2DM patients with higher co-
morbidity levels are over-represented in our study.
Our data show that patients receiving SU therapy
(mono or combo) differ significantly from other T2DM
patients treated with MET in any combination: they tend
to be older, have greater comorbidity and are more often
female. So, for example, the mean ages of patients who
received MET mono, GLP-1+OAD, GLP-1+OAD+insu-
lin or MET+DPP4 combination therapy were 69.0, 57.5,
58.0 and 66.8 years, respectively. In comparison, the
mean ages of patients who received SU mono or SU
+MET combination therapy were 76.8 and 72.2 years, re-
spectively. This makes a real-world comparison of SU
with GLP-1s/DPP4s a challenging task because, obvi-
ously, new antidiabetic agents address completely differ-
ent T2DM patient cohorts in real-life practice than SUs.
Consequently, a substantial number of patients were ex-
cluded in the PSM comparisons. To reduce the bias risk
for those patients included in the PSM cohorts, we used
all available variables that significantly influenced group
exposition, even if there was a certain overlap between
these variables, as was the case with CCI and aDCSI.
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Limitations
The current study is an observational cohort study with
several limitations commonly associated with observa-
tional studies. First of all, it is limited with regard to its
sample size and, more importantly, to the relatively short
duration of follow-up. In addition, a significant number
of patients was lost to follow-up, with 42.8 % of SU
monotherapy patients and 47.8 % of SU+MET combin-
ation therapy patients discontinuing their treatment
(treatment gap >180 days or prescription of another
agent) or suffering a fatal event within the first 12 months
after initiation of therapy. Thus, these patients had a much
shorter follow-up than the planned minimum period of
12 months, and they were censored prematurely before
the end of the study period.
Finally, certain information concerning several risk
factors known from patient demographics and clinical
characteristics associated with event risk were not avail-
able in our claims data. This included information about
HbA1C [9, 38–40] and blood pressure [41, 42], which
may predict MACE/mortality based on a U-curve pat-
tern [3]. It also included preclinical atherosclerosis [43],
specific GFR values [44], level of physical activity [45]
and total or low density lipoprotein (LDL)-cholesterol
values, which have been found to be independent cardio-
vascular risk factors in other T2DM studies [38, 46].
Conclusions
Our study suggests that SU monotherapy may be associ-
ated with an increased risk of mortality, MACE, T2DM
hospitalizations and/or all-cause events, compared to
MET monotherapy. Current German and European
guidelines mostly recommend the use of SU as second-
line therapy or, in case of MET contraindications, the
use of SU as first-line therapy, and SU therapy is still
prescribed in an important part of T2DM patients in
Germany [8, 9]. Our results indicate that in considering
SU therapy, the associated cardiovascular risk should
also be taken into account.
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Additional file 1: Table S1. Components of the aDSCI. The table
contains the components of the adapted Diabetes Complications
Severity Index and describes the score methodology used, based on
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Additional file 2: Table S2. Charlson Comorbidity Index (CCI) and its
components. The table outlines the components of the Charlson
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Additional file 3: Figure S3. Kaplan-Meier (KM) curves for crude all-cause
death rates, macrovascular event rates and T2DM-related hospitalizations
for patients with either MET or SU monotherapy. The figure shows KM
curves representing the percentage of event-free patients (all-cause event
as well as mortality, MACE and T2DM-related hospitalizations) for two
T2DM-incident cohorts: patients who received SU monotherapy and
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Additional file 4: Figure S1. Distribution of propensity scores as
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figure describes the overlap of propensity scores in Cohort 1, incorporating
patients who received MET/SU monotherapy. (TIF 198 kb)
Additional file 5: Figure S5. Multivariable Cox regression models
estimating time to event for four outcome categories (MET/SU
monotherapy). The figure shows the results of the multivariable Cox
regression analysis with regard to independent factors influencing
time until an event (all-cause event as well as mortality, MACE and
T2DM-related hospitalizations in separate models) in the T2DM-incident
sample that received either SU or MET monotherapy. (TIF 164 kb)
Additional file 6: Figure S4. Kaplan-Meier (KM) curves for all-cause
death rates, macrovascular event rates and T2DM-related hospitalizations
for patients with either MET or SU monotherapy (PS matched groups).
The figure shows KM curves representing the percentage of event-free
patients (all-cause event as well as mortality, MACE and T2DM-related
hospitalizations) for two T2DM-incident cohorts: patients who received
SU monotherapy and patients who received MET monotherapy. Cohorts
are matched by PSM. Observation started with the first observed SU/MET
prescription. (TIF 546 kb)
Additional file 7: Figure S2. Distribution of propensity scores as
calculated by logistic regression for SU+MET and DPP4-MET combination
therapy users. This figure describes the overlap of propensity scores in
Cohort 2, incorporating patients who received SU+MET or DPP4-MET
combination therapy. (TIF 227 kb)
Additional file 8: Figure S8. Multivariable Cox regression models
estimating time to event for four outcome categories (MET+SU/MET
+DPP-4 therapy). Factors associated with event risk. The figure shows
the results of the multivariable Cox regression analysis with regard to
independent factors influencing time until an event (all-cause event
as well as mortality, MACE and T2DM-related hospitalizations in separate
models) in the T2DM-prevalent sample that received either SU+MET or
DPP4+MET combination therapy. (TIF 160 kb)
Additional file 9: Figure S6. Kaplan-Meier (KM) curves for crude all-cause
death rates, macrovascular event rates and T2DM-related hospitalizations for
patients with either MET+SU or MET+DPP-4 therapy. The figure shows KM
curves representing the percentage of event-free patients (all-cause event
as well as mortality, MACE and T2DM-related hospitalizations) for the two
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prescription of the second combination agent. (TIF 604 kb)
Additional file 10: Figure S7. Kaplan-Meier (KM) curves for crude
all-cause death rates, macrovascular event rates and T2DM-related
hospitalizations for patients with either MET+SU or MET+DPP-4
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the percentage of event-free patients (all-cause event as well as mortality,
MACE and T2DM-related hospitalizations) for the two cohorts defined
above. Observation started with the first observed prescription of the
second combination agent. (TIF 629 kb)
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